You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

307 Results
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Dec 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    lanreotide
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal)
Intent: Palliative
Jan 2024
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Jan 2024
Drug
Other Name(s): CeeNU®
Aug 2024
Drug
Other Name(s): Imjudo®
Apr 2024
Drug
Other Name(s): Yervoy®
Aug 2024
Drug
Nov 2024
Drug
Other Name(s): Sarclisa®
Mar 2024
Drug
Other Name(s): Leukeran®
Nov 2024
Drug
Nov 2024
Drug
Other Name(s): Opdivo®
Oct 2024

Pages